AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10561302
Drug: Short interval
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short interval (SI) group: surgery within 2 weeks after completion of radiation therapy
Trial: 10561302
Drug: Long interval
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long interval (LI) group: surgery 6 to 8 weeks after completion of radiation therapy
Trial: 7995909
Drug: Gore-Tex sling
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gore-Tex sling treatment (alone or in combination with prolapsus cure)
Trial: 7995909
Drug: Gore-Tex sling
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gore-Tex sling treatment
Trial: 31090348
Drug: P-PRP (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-PRP (2.5 mL injected at the bone graft site)
Trial: 31090348
Drug: L-PRP (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PRP (2.5 mL injected at the bone graft site)
Trial: 31090348
Drug: L-PRP
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PRP
Trial: 12535753
Drug: Fenofibrate intervention
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate intervention (not specified dosage or duration)
Trial: 10433131
Drug: Combined psychoeducational
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined psychoeducational and cognitive treatment including key-person counselling
Trial: 8688757
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg or 40 mg daily
Trial: 1424414
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg per day)
Trial: 2870547
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate (100 mg per day in two doses)
Trial: 30184181
Drug: TOL-463 vaginal
RxNorm normalized name: TOL-101
DrugBank: TOL-101 (DB16980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOL-463 vaginal gel
Trial: 28183146
Drug: Prenatal ultrasound
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal ultrasound monitoring, interdisciplinary team approach, planned delivery through cesarean section, postnatal coverage of the intestine with a silastic bag, first intervention within the first 6 hours after birth, attempt of primary abdominal wall closure, perioperative antibiotic treatment.
Trial: 28183146
Drug: Fetal therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fetal therapy, preterm delivery, lack of abdominal pressure monitoring.
Trial: 27876742
Drug: Neuromidin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromidin therapy (1.5 month-long course) in addition to standard treatment
Trial: 27876742
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without Neuromidin
Trial: 12177686
Drug: Galantamine 24
RxNorm normalized name: galantamine 24 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 24 mg/day for 12 months
Trial: 7059442
Drug: Lofexidine 0.1
RxNorm normalized name: lofexidine 0.18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lofexidine 0.1 mg
Trial: 7059442
Drug: Lofexidine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lofexidine 0.3 mg
Trial: 7059442
Drug: Lofexidine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lofexidine 0.6 mg
Trial: 7059442
Drug: Lofexidine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lofexidine (mean threshold dose)
Trial: 28629250
Drug: Ginger (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (500 mg twice daily)
Trial: 28629250
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 (40 mg twice daily)
Trial: 2081722
Drug: Ciprofloxacin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (750 mg or 1000 mg bd)
Trial: 2081722
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (rifampicin plus doxycycline)
Trial: 370367
Drug: Sodium acetylo-salicylate
RxNorm normalized name: Sodium Salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium acetylo-salicylate (2 g per os) during heat exposure at 37 degrees C
Trial: 370367
Drug: Sodium acetylo-salicylate
RxNorm normalized name: Sodium Salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium acetylo-salicylate (2 g per os) during exercise at 25 degrees C
Trial: 23219660
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (Arm 1)
Trial: 21965475
Drug: High-dose epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose epirubicin plus cyclophosphamide (EC) - E 120 mg/m², C 600 mg/m² for four cycles every 21 days
Trial: 21965475
Drug: Docetaxel (D)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (D) 100 mg/m² followed by four cycles of EC for four cycles every 21 days
Trial: 11846927
Drug: Postoperative external
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative external beam radiation therapy
Trial: 9751087
Drug: cA2 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cA2 at 3 or 10 mg/kg with or without MTX
Trial: 9751087
Drug: cA2 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cA2 at 1 mg/kg without MTX
Trial: 9751087
Drug: cA2 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cA2 at 1 mg/kg with MTX
Trial: 9751087
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus low-dose MTX
Trial: 9751087
Drug: cA2 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cA2 at 10 mg/kg with MTX
Trial: 9751087
Drug: cA2 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cA2 at 1 mg/kg alone
Trial: 8176574
Drug: Clarithromycin suspension
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin suspension at 3.75, 7.5, and 15 mg/kg per dose every 12 hours
Trial: 8176574
Drug: Clarithromycin suspension
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin suspension at 15 mg/kg per dose every 12 hours
Trial: 8176574
Drug: Clarithromycin suspension
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin suspension
Trial: 28843973
Drug: Carrot soup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrot soup with MSG (5 g, 1% w/w)
Trial: 28843973
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein enriched carrot soup with MSG (5 g, 1% w/w)
Trial: 17851077
Drug: Concomitant tumour
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant tumour bed boost (CB) with whole breast radiotherapy (RT) delivering 50Gy and an electron boost of 12.5Gy in 5 weekly fractions.
Trial: 16375760
Drug: Walking Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walking Program (WP) and Vitamin Supplements
Trial: 16375760
Drug: Walking Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walking Program (WP) and Placebo Supplements
Trial: 16375760
Drug: Placebo Activity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Activity Program (PAP) and Vitamin Supplements
Trial: 16375760
Drug: Placebo Activity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Activity Program (PAP) and Placebo Supplements
Trial: 12452877
Drug: Oral antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antifungal agents
Trial: 6114845
Drug: Dihydroergotamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (2 mg)
Trial: 6114845
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (2 mg dihydroergotamine and 20 mg etilefrine)
Trial: 29358870
Drug: Study regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study regimen (oral sulfate solution 89 mL with diatrizoate solution: boost 1 = 60 mL, boost 2 = 30 mL)
Trial: 29358870
Drug: Control regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control regimen (oral sulfate solution 89 mL)
Trial: 25605861
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus trastuzumab (arms B and C)
Trial: 17624483
Drug: Exercise programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise programme provided by public health nurses, comprising a weekly exercise class of 2 hours for 17 weeks, supplemented by daily home exercises
Trial: 15112866
Drug: ReN1869 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ReN1869 25 mg
Trial: 15112866
Drug: ReN1869 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ReN1869 50 mg
Trial: 15112866
Drug: ReN1869 (subchronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ReN1869 (subchronic mode, one week treatment)
Trial: 2735337
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one tablet four times per day)
Trial: 2735337
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg three times per day)
Trial: 2735337
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g four times per day) plus Ranitidine (150 mg three times per day)
Trial: 2735337
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus Ranitidine (150 mg three times per day)
Trial: 24715602
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (VP) 8% gel
Trial: 15066608
Drug: High-fiber (13.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber (13.5 g/d) wheat bran fiber cereal supplement
Trial: 15066608
Drug: Low-fiber (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fiber (2.0 g/d) wheat bran fiber cereal supplement
Trial: 11495405
Drug: Buffered lidocaine
RxNorm normalized name: buffered lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered lidocaine with epinephrine solution
Trial: 11495405
Drug: Combination buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination buffered lidocaine with epinephrine plus hyaluronidase solution
Trial: 2648144
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid mouthwash (10 ml of a 4.8 percent aqueous solution)
Trial: 31570881
Drug: Colorectal cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colorectal cancer immunotherapy
Trial: 21616946
Drug: Acamprosate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (2 g/day)
Trial: 10792154
Drug: Controlled-release oxybutynin
RxNorm normalized name: oxybutynin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release oxybutynin tablets (10 mg once daily)
Trial: 10792154
Drug: Conventional oxybutynin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oxybutynin tablets (5 mg twice daily)
Trial: 9054629
Drug: 5 x
RxNorm normalized name: PAD,ABDOMINAL 5 X 9 STERILE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 x RDI VITE supplement (provided in cereal)
Trial: 9054629
Drug: 30 x
RxNorm normalized name: Lead 30 X Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 x RDI VITE supplement (provided in capsules)
Trial: 8311570
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 6 mg/kg dose of DEC
Trial: 8311570
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 6 mg/kg dose of DEC preceded by 1 mg/kg DEC primer
Trial: 8311570
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 220 micrograms/kg dose of ivermectin
Trial: 8311570
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 200 micrograms/kg dose of ivermectin preceded by a 20 micrograms/kg ivermectin primer
Trial: 8311570
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 400 micrograms/kg dose of ivermectin preceded by a 20 micrograms/kg ivermectin primer
Trial: 3085896
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g elemental calcium plus 400 U Vitamin D
Trial: 31999839
Drug: Dasatinib 100
RxNorm normalized name: dasatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 100 mg daily
Trial: 26951136
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg bid per os for 3 days starting the day before biopsy
Trial: 26951136
Drug: Meropenem 1
RxNorm normalized name: meropenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 1 g intravenously 1 hour prior to the procedure
Trial: 24681657
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of ACEIs and ARBs on the day of surgery
Trial: 24681657
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of ACEIs and ARBs
Trial: 22691900
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (OM) 20 mg (weeks 1-4), 40 mg (weeks 5-8)
Trial: 22691900
Drug: Losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan potassium (LOS) 50 mg (weeks 1-4), 100 mg (weeks 5-8)
Trial: 15246631
Drug: HPV11 L1
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV11 L1 VLP vaccine (10 microg)
Trial: 15246631
Drug: HPV11 L1
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV11 L1 VLP vaccine (20 microg)
Trial: 15246631
Drug: HPV11 L1
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV11 L1 VLP vaccine (50 microg)
Trial: 15246631
Drug: HPV11 L1
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV11 L1 VLP vaccine (100 microg)
Trial: 15246631
Drug: HPV16 L1
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV16 L1 VLP vaccine (10 microg)
Trial: 15246631
Drug: HPV16 L1
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV16 L1 VLP vaccine (40 microg)
Trial: 15246631
Drug: HPV16 L1
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV16 L1 VLP vaccine (80 microg)
Trial: 9304946
Drug: Enteroclysis therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteroclysis therapy
Trial: 8392360
Drug: Terbutaline 7.5
RxNorm normalized name: terbutaline 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 7.5 mg, administered twice daily for 1 week
Trial: 8392360
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg, administered twice daily for 1 week
Trial: 3511328
Drug: Bubble oxygenator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bubble oxygenator with methylprednisolone sodium succinate (30 mg/kg)
Trial: 3763651
Drug: Flupenthixol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixol (0.5 mg for the first week, then doubled for 3 weeks)
Trial: 3763651
Drug: Diazepam (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (2.5 mg for the first week, then doubled for 3 weeks)
Trial: 24565296
Drug: Propofol via
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol via patient‐controlled analgesia device (400 μg.kg(‐1), 5‐minute lockout interval, no basal infusion)
Trial: 24565296
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion using the same settings as Group P
Trial: 19004308
Drug: Low Intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Intensity Laser Therapy (LILT) - Infrared laser (780 nm, 70 mw, 60s, 105J/cm2), applied twice per week for a total of eight sessions
Trial: 10723834
Drug: Post-treatment self-efficacy
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment self-efficacy
Trial: 1532198
Drug: Cl2MDP (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cl2MDP (300 mg IV for 7 days, then 200 mg IM for 14 days)
Trial: 1532198
Drug: Cl2MDP (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cl2MDP (1,200 mg/d orally) plus chemotherapy (group B)
Trial: 1532198
Drug: Cl2MDP treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cl2MDP treatment in osteoblastic metastases
Trial: 18617099
Drug: Mini-implants as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-implants as anchor units (G1)
Trial: 11876261
Drug: Plant sterol
RxNorm normalized name: plant sterol complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol esters (PSE) at a dosage of 3.6 g/d in salad dressings (ranch or Italian) for 3 weeks
Trial: 9918342
Drug: Tolcapone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone (200 mg three times daily)
Trial: 9918342
Drug: Bromocriptine (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (titrated from 1.25 mg once daily to a mean final dose of 22.4 mg/day)
Trial: 7554756
Drug: Dobutamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine infusion (15 micrograms min‐1 kg‐1)
Trial: 6101676
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of intravaginal purified porcine relaxin
Trial: 31200830
Drug: Cisplatin added
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin added to single-agent chemotherapy
Trial: 31200830
Drug: Single-agent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent chemotherapy without cisplatin
Trial: 25802471
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + GIMM (GI microbiome modulator)
Trial: 23981773
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 5,000 IU daily
Trial: 23981773
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 10,000 IU daily
Trial: 17157654
Drug: Acetone‐precipitated extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetone‐precipitated extract containing 0.6 mug Can f 1 per 0.5 mL maintenance dose
Trial: 17157654
Drug: Acetone‐precipitated extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetone‐precipitated extract containing 3.0 mug Can f 1 per 0.5 mL maintenance dose
Trial: 17157654
Drug: Acetone‐precipitated extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetone‐precipitated extract containing 15.0 mug Can f 1 per 0.5 mL maintenance dose
Trial: 14511168
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (n=10)
Trial: 10575661
Drug: GLN-antioxidants (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLN-antioxidants (40 g/d)
Trial: 10575661
Drug: Control (glycine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (glycine 40 g/d)
Trial: 8701786
Drug: Mestranol plus
RxNorm normalized name: Mestranol
DrugBank: Mestranol (DB01357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mestranol plus paramethasone (80 micrograms + 6 mg/day for 10 days)
Trial: 6224685
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg norfloxacin twice daily for ten days